ImmunoPrecise Antibodies Net Profit Margin 2022-2025 | IPA
ImmunoPrecise Antibodies net profit margin from 2022 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
| ImmunoPrecise Antibodies Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2025-01-31 | $0.02B | $-0.03B | -194.12% |
| 2024-10-31 | $0.02B | $-0.02B | -111.11% |
| 2024-07-31 | $0.02B | $-0.02B | -105.26% |
| 2024-04-30 | $0.02B | $-0.02B | -105.26% |
| 2024-01-31 | $0.02B | $-0.01B | -61.11% |
| 2023-10-31 | $0.02B | $-0.01B | -70.59% |
| 2023-07-31 | $0.02B | $-0.02B | -100.00% |
| 2023-04-30 | $0.02B | $-0.02B | -125.00% |
| 2023-01-31 | $0.02B | $-0.02B | -125.00% |
| 2022-10-31 | $0.02B | $-0.02B | -125.00% |
| 2022-07-31 | $0.02B | $-0.02B | -112.50% |
| 2022-04-30 | $0.02B | $-0.01B | -87.50% |
| 2022-01-31 | $0.02B | $-0.01B | -87.50% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.022B | $0.018B |
| ImmunoPrecise Antibodies Ltd. is a technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. ImmunoPrecise Antibodies Ltd. is based in VICTORIA. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $37.877B | 52.32 |
| Hims & Hers Health (HIMS) | United States | $10.991B | 115.05 |
| Tempus AI (TEM) | United States | $8.988B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $4.774B | 74.60 |
| IRhythm Technologies (IRTC) | United States | $4.316B | 0.00 |
| Privia Health (PRVA) | United States | $2.756B | 206.54 |
| Enovis (ENOV) | United States | $1.947B | 12.05 |
| Schrodinger (SDGR) | United States | $1.721B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.712B | 0.00 |
| Phreesia (PHR) | United States | $1.426B | 0.00 |
| Omnicell (OMCL) | United States | $1.202B | 21.21 |
| Azenta (AZTA) | United States | $1.162B | 54.08 |
| 10x Genomics (TXG) | United States | $0.991B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.573B | 0.00 |
| Talkspace (TALK) | United States | $0.530B | 157.25 |
| Butterfly Network (BFLY) | United States | $0.527B | 0.00 |
| Veradigm (MDRX) | United States | $0.486B | 0.00 |
| Standard BioTools (LAB) | United States | $0.403B | 0.00 |
| TruBridge (TBRG) | United States | $0.381B | 0.00 |
| Claritev (CTEV) | United States | $0.329B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.286B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.218B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.200B | 0.00 |
| Pulmonx (LUNG) | United States | $0.138B | 0.00 |
| American Well (AMWL) | United States | $0.106B | 0.00 |
| Retrieve Medical Holdings (RMHI) | United States | $0.095B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.092B | 0.00 |
| CareCloud (CCLD) | United States | $0.091B | 3.45 |
| MDxHealth SA (MDXH) | Belgium | $0.080B | 0.00 |
| 111 (YI) | China | $0.069B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.063B | 0.00 |
| HeartBeam (BEAT) | United States | $0.062B | 0.00 |
| Outset Medical (OM) | United States | $0.041B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.040B | 0.00 |
| Zhongchao (ZCMD) | China | $0.033B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.016B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.016B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.012B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.011B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.009B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.009B | 0.00 |
| Movano (MOVE) | United States | $0.006B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |